Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma
Teclistamab (JNJ-64007957) is a bispecific BCMA x CD3 antibody that induces T cell-mediated cytotoxicity against BCMA-expressing myeloma cells. Initial results from an ongoing study of teclistamab in RRMM (NCT03145181) are presented.
Teclistamab has manageable safety across all doses explored. A 78% overall response rate was observed at the highest weekly treatment dose in pts with advanced RRMM, supporting further evaluation of teclistamab in expansion cohorts.
Clinical trial information: NCT03145181
Please subscribe to our channel!
Subscribe to International Myeloma Foundation: [ Ссылка ]
Visit our website at: [ Ссылка ]
Find us online:
Facebook: [ Ссылка ]
Google+: [ Ссылка ]
IMF on twitter: @IMFMyeloma ([ Ссылка ])
Dr. Durie on twitter: @BrianDurieMD ([ Ссылка ])
Support the IMF! [ Ссылка ]
Category
Nonprofits & Activism
License
Standard YouTube License
